{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:25:39Z","timestamp":1793953539918,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Jiangxi, China","award":["20224BAB216016"],"award-info":[{"award-number":["20224BAB216016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-025-03663-9","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:11:33Z","timestamp":1761653493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Knowledge domain and emerging trends on the SGLT2 inhibitor dapagliflozin for heart failure: a bibliometric analysis from 2012 to 2024"],"prefix":"10.1186","volume":"20","author":[{"given":"Mengxuan","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"36","key":"3663_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"6","key":"3663_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027852","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu S, Yin X, Xie C, Xue J, Zhu M, et al. Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the global burden of disease 2019 study. J Am Heart Assoc. 2023;12(6):e027852.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"3663_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008406","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Chai K, Du M, Wang S, Cai JP, Li Y, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail. 2021;14(10):e008406.","journal-title":"Circ Heart Fail"},{"issue":"9","key":"3663_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ejhf.822","volume":"19","author":"MA Mamas","year":"2017","unstructured":"Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19(9):1095\u2013104.","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"3663_CR5","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3663_CR6","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1097\/MJT.0000000000000794","volume":"25","author":"E Gracia","year":"2018","unstructured":"Gracia E, Singh P, Collins S, Chioncel O, Pang P, Butler J. The vulnerable phase of heart failure. Am J Ther. 2018;25(4):e456\u201364.","journal-title":"Am J Ther"},{"issue":"17","key":"3663_CR7","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272\u201387.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"3663_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606\u201319.","journal-title":"Circ Heart Fail"},{"key":"3663_CR9","doi-asserted-by":"crossref","unstructured":"Darvish M, Shakoor A, Feyz L, Schaap J, van Mieghem NM, de Boer RA et al. Heart failure: assessment of the global economic burden. Eur Heart J. 2025.[Epub ahead of print].","DOI":"10.1093\/eurheartj\/ehaf323"},{"issue":"10","key":"3663_CR10","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc10-0612","volume":"33","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217\u201324.","journal-title":"Diabetes Care"},{"issue":"9","key":"3663_CR11","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","volume":"28","author":"PS Jhund","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28(9):1956\u201364.","journal-title":"Nat Med"},{"issue":"14","key":"3663_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohl\u00e1vek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353\u201368.","journal-title":"JAMA"},{"issue":"4","key":"3663_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"3663_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"12","key":"3663_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"key":"3663_CR16","doi-asserted-by":"publisher","first-page":"939433","DOI":"10.3389\/fimmu.2022.939433","volume":"13","author":"F Wu","year":"2022","unstructured":"Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, et al. Knowledge mapping of exosomes in autoimmune diseases: a bibliometric analysis (2002\u20132021). Front Immunol. 2022;13:939433.","journal-title":"Front Immunol"},{"key":"3663_CR17","first-page":"724","volume":"2005","author":"MB Synnestvedt","year":"2005","unstructured":"Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;2005:724\u20138.","journal-title":"AMIA Annu Symp Proc"},{"issue":"2","key":"3663_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523\u201338.","journal-title":"Scientometrics"},{"issue":"3","key":"3663_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5195\/jmla.2022.1434","volume":"110","author":"H Arruda","year":"2022","unstructured":"Arruda H, Silva ER, Lessa M, Proen\u00e7a D Jr, Bartholo R. VOSviewer and bibliometrix. J Med Libr Assoc. 2022;110(3):392\u20135.","journal-title":"J Med Libr Assoc"},{"issue":"4","key":"3663_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.pcad.2019.07.005","volume":"62","author":"V Garg","year":"2019","unstructured":"Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019;62(4):349\u201357.","journal-title":"Prog Cardiovasc Dis"},{"issue":"15","key":"3663_CR21","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"3663_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"SR Yurista","year":"2019","unstructured":"Yurista SR, Sillj\u00e9 HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, et al. Sodium-glucose co-transporter 2 Inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"3663_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation"},{"issue":"10254","key":"3663_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"11","key":"3663_CR25","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360.","journal-title":"Nat Med"},{"issue":"14","key":"3663_CR26","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jacc.2022.07.021","volume":"80","author":"JW Cunningham","year":"2022","unstructured":"Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol. 2022;80(14):1302\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3663_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","volume":"81","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Bhatt AS, Claggett BL, Vaduganathan M, Kulac IJ, Lam CSP, et al. Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol. 2023;81(5):460\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"3663_CR28","first-page":"807","volume":"9","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Wheeler DC, Stef\u00e1nsson BV, Jongs N, Postmus D, Correa-Rotter R, et al. Effects of Dapagliflozin in patients with kidney disease, with and without heart failure. JACC: Heart Failure. 2021;9(11):807\u201320.","journal-title":"JACC: Heart Failure"},{"issue":"5","key":"3663_CR29","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s12325-021-01735-5","volume":"38","author":"A Mima","year":"2021","unstructured":"Mima A. Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease. Adv Ther. 2021;38(5):2201\u201312.","journal-title":"Adv Ther"},{"key":"3663_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175521","volume":"942","author":"RS Farias","year":"2023","unstructured":"Farias RS, Silva-Aguiar RP, Teixeira DE, Gomes CP, Pinheiro AAS, Peruchetti DB, et al. Inhibition of SGLT2 co-transporter by Dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease. Eur J Pharmacol. 2023;942:175521.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"3663_CR31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","volume":"143","author":"PS Jhund","year":"2021","unstructured":"Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, B\u00f6hm M, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298\u2013309.","journal-title":"Circulation"},{"issue":"7","key":"3663_CR32","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ejhf.2915","volume":"25","author":"S Chatur","year":"2023","unstructured":"Chatur S, Cunningham JW, Vaduganathan M, Mc Causland FR, Claggett BL, Desai AS, et al. Renal and blood pressure effects of Dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: insights from the DELIVER trial. Eur J Heart Fail. 2023;25(7):1170\u20135.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3663_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","volume":"8","author":"FR Mc Causland","year":"2023","unstructured":"Mc Causland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2023;8(1):56\u201365.","journal-title":"JAMA Cardiol"},{"issue":"16","key":"3663_CR34","doi-asserted-by":"publisher","first-page":"7642","DOI":"10.1111\/jcmm.16601","volume":"25","author":"J Tian","year":"2021","unstructured":"Tian J, Zhang M, Suo M, Liu D, Wang X, Liu M, et al. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats. J Cell Mol Med. 2021;25(16):7642\u201359.","journal-title":"J Cell Mol Med"},{"issue":"12","key":"3663_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101334","volume":"4","author":"Q Wu","year":"2023","unstructured":"Wu Q, Yao Q, Hu T, Yu J, Jiang K, Wan Y, et al. Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. Cell Rep Med. 2023;4(12):101334.","journal-title":"Cell Rep Med"},{"issue":"1","key":"3663_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","volume":"19","author":"M Arow","year":"2020","unstructured":"Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, et al. Sodium-glucose cotransporter 2 inhibitor dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020;19(1):7.","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"3663_CR37","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3663_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ki.1983.72","volume":"23","author":"BM Brenner","year":"1983","unstructured":"Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int. 1983;23(4):647\u201355.","journal-title":"Kidney Int"},{"issue":"15","key":"3663_CR39","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-025-03663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-025-03663-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-025-03663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:11:34Z","timestamp":1761653494000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-025-03663-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3663"],"URL":"https:\/\/doi.org\/10.1186\/s13019-025-03663-9","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}